1271 related articles for article (PubMed ID: 24018362)
21. Transferrin-conjugated magnetic silica PLGA nanoparticles loaded with doxorubicin and paclitaxel for brain glioma treatment.
Cui Y; Xu Q; Chow PK; Wang D; Wang CH
Biomaterials; 2013 Nov; 34(33):8511-20. PubMed ID: 23932498
[TBL] [Abstract][Full Text] [Related]
22. A transferrin variant as the targeting ligand for polymeric nanoparticles incorporated in 3-D PLGA porous scaffolds.
Lopes AM; Chen KY; Kamei DT
Mater Sci Eng C Mater Biol Appl; 2017 Apr; 73():373-380. PubMed ID: 28183621
[TBL] [Abstract][Full Text] [Related]
23. Targeted delivery of doxorubicin using stealth liposomes modified with transferrin.
Li X; Ding L; Xu Y; Wang Y; Ping Q
Int J Pharm; 2009 May; 373(1-2):116-23. PubMed ID: 19429296
[TBL] [Abstract][Full Text] [Related]
24. Actively targeted cetuximab conjugated gamma-poly(glutamic acid)-docetaxel nanomedicines for epidermal growth factor receptor over expressing colon cancer cells.
Maya S; Sarmento B; Lakshmanan VK; Menon D; Jayakumar R
J Biomed Nanotechnol; 2014 Aug; 10(8):1416-28. PubMed ID: 25016642
[TBL] [Abstract][Full Text] [Related]
25. Poly(lactide)-vitamin E derivative/montmorillonite nanoparticle formulations for the oral delivery of Docetaxel.
Feng SS; Mei L; Anitha P; Gan CW; Zhou W
Biomaterials; 2009 Jul; 30(19):3297-306. PubMed ID: 19299012
[TBL] [Abstract][Full Text] [Related]
26. The application of nanoparticles in cancer immunotherapy: Targeting tumor microenvironment.
Yang M; Li J; Gu P; Fan X
Bioact Mater; 2021 Jul; 6(7):1973-1987. PubMed ID: 33426371
[TBL] [Abstract][Full Text] [Related]
27. Anti-tumor activity of paclitaxel through dual-targeting carrier of cyclic RGD and transferrin conjugated hyperbranched copolymer nanoparticles.
Xu Q; Liu Y; Su S; Li W; Chen C; Wu Y
Biomaterials; 2012 Feb; 33(5):1627-39. PubMed ID: 22118775
[TBL] [Abstract][Full Text] [Related]
28. Physicochemical and biological characterization of targeted, nucleic acid-containing nanoparticles.
Bartlett DW; Davis ME
Bioconjug Chem; 2007; 18(2):456-68. PubMed ID: 17326672
[TBL] [Abstract][Full Text] [Related]
29. Tumor cell targeting of transferrin-PEG-TNF-alpha conjugate via a receptor-mediated delivery system: design, synthesis, and biological evaluation.
Jiang YY; Liu C; Hong MH; Zhu SJ; Pei YY
Bioconjug Chem; 2007; 18(1):41-9. PubMed ID: 17226956
[TBL] [Abstract][Full Text] [Related]
30. PEGylated J591 mAb loaded in PLGA-PEG-PLGA tri-block copolymer for targeted delivery: in vitro evaluation in human prostate cancer cells.
Moffatt S; Cristiano RJ
Int J Pharm; 2006 Jul; 317(1):10-3. PubMed ID: 16713147
[TBL] [Abstract][Full Text] [Related]
31. Ligand-targeted theranostic nanomedicines against cancer.
Yao VJ; D'Angelo S; Butler KS; Theron C; Smith TL; Marchiò S; Gelovani JG; Sidman RL; Dobroff AS; Brinker CJ; Bradbury ARM; Arap W; Pasqualini R
J Control Release; 2016 Oct; 240():267-286. PubMed ID: 26772878
[TBL] [Abstract][Full Text] [Related]
32. Paclitaxel loaded folic acid targeted nanoparticles of mixed lipid-shell and polymer-core: in vitro and in vivo evaluation.
Zhao P; Wang H; Yu M; Liao Z; Wang X; Zhang F; Ji W; Wu B; Han J; Zhang H; Wang H; Chang J; Niu R
Eur J Pharm Biopharm; 2012 Jun; 81(2):248-56. PubMed ID: 22446630
[TBL] [Abstract][Full Text] [Related]
33. Ligand-based targeted delivery of a peptide modified nanocarrier to endothelial cells in adipose tissue.
Hossen MN; Kajimoto K; Akita H; Hyodo M; Ishitsuka T; Harashima H
J Control Release; 2010 Oct; 147(2):261-8. PubMed ID: 20647023
[TBL] [Abstract][Full Text] [Related]
34. Using doxorubicin and siRNA-loaded heptapeptide-conjugated nanoparticles to enhance chemosensitization in epidermal growth factor receptor high-expressed breast cancer cells.
Liu CW; Lin WJ
J Drug Target; 2013 Sep; 21(8):776-86. PubMed ID: 23829387
[TBL] [Abstract][Full Text] [Related]
35. Self-aggregated pegylated poly (trimethylene carbonate) nanoparticles decorated with c(RGDyK) peptide for targeted paclitaxel delivery to integrin-rich tumors.
Jiang X; Sha X; Xin H; Chen L; Gao X; Wang X; Law K; Gu J; Chen Y; Jiang Y; Ren X; Ren Q; Fang X
Biomaterials; 2011 Dec; 32(35):9457-69. PubMed ID: 21911250
[TBL] [Abstract][Full Text] [Related]
36. Peptide ligand-modified nanomedicines for targeting cells at the tumor microenvironment.
David A
Adv Drug Deliv Rev; 2017 Sep; 119():120-142. PubMed ID: 28506743
[TBL] [Abstract][Full Text] [Related]
37. Enhanced anti-tumor efficacy by co-delivery of doxorubicin and paclitaxel with amphiphilic methoxy PEG-PLGA copolymer nanoparticles.
Wang H; Zhao Y; Wu Y; Hu YL; Nan K; Nie G; Chen H
Biomaterials; 2011 Nov; 32(32):8281-90. PubMed ID: 21807411
[TBL] [Abstract][Full Text] [Related]
38. Targeting Nanomedicines to Prostate Cancer: Evaluation of Specificity of Ligands to Two Different Receptors In Vivo.
Pearce AK; Fuchs AV; Fletcher NL; Thurecht KJ
Pharm Res; 2016 Oct; 33(10):2388-99. PubMed ID: 27225496
[TBL] [Abstract][Full Text] [Related]
39. Cyclic RGD conjugated poly(ethylene glycol)-co-poly(lactic acid) micelle enhances paclitaxel anti-glioblastoma effect.
Zhan C; Gu B; Xie C; Li J; Liu Y; Lu W
J Control Release; 2010 Apr; 143(1):136-42. PubMed ID: 20056123
[TBL] [Abstract][Full Text] [Related]
40. In vivo fate of folate-targeted polyethylene-glycol liposomes in tumor-bearing mice.
Gabizon A; Horowitz AT; Goren D; Tzemach D; Shmeeda H; Zalipsky S
Clin Cancer Res; 2003 Dec; 9(17):6551-9. PubMed ID: 14695160
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
